<DOC>
	<DOCNO>NCT01989884</DOCNO>
	<brief_summary>Italian Study On The Efficacy Of Ortataxel In Recurrent Glioblastoma</brief_summary>
	<brief_title>An Efficacy Study Of Ortataxel In Recurrent Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>Histologically confirm GBM . GBM recurrence/progression surgery ( biopsy ) , standard radiotherapy chemotherapy Temozolomide . Imaging confirmation first tumor progression regrowth define RANO criterion . No one prior line chemotherapy ( Temozolomide ) . Recovery toxic effect prior therapy . Patients undergone recent surgery recurrent progressive tumor eligible provide : 1 . Surgery must confirm recurrence . 2 . A minimum 14 day must elapse day surgery registration . For core needle biopsy , minimum 7 day must elapse prior registration . 3 . Craniotomy intracranial biopsy site must adequately heal free drainage cellulitis , underlie cranioplasty must appear intact time registration . Age ≥ 18 year . Willingness ability provide write informed consent comply study protocol judge investigator . KarnofskyPS ≥ 60 % . Stable decrease dose corticosteroid within 5 day prior registration . Patients unable undergo brain MRI scan gadolinium ( iv ) . Preexisting peripheral neuropathy , grade ≥ 2 . History intracranial abscess within 6 month prior registration . Anticipation need major surgical procedure course trial . Treatment enzyme induce antiepileptic agent allow . However , patient whose anticonvulsant change nonenzymeinducing antiepileptic drug eligible entry 1week `` washout '' period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>